Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: www.sandoz.ca
Number of Employees: 900
Year Founded: 1980
Total Amount Raised (CAD mm)†: 24.00
Total Rounds of Funding**:1
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Sandoz Canada Inc. develops, manufactures, markets, and distributes generic, biosimilar, and specialty pharmaceutical products. Its portfolio includes various oral, topical, rectal, ophthalmic, and injectable generic products in various forms, such as suspensions, solutions, tablets, capsules, creams, ointments, suppositories, and gelcaps; Sandoz Lenalidomide, a generic for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities; and various formats, including ampoules, vials, bottles, minibags, and transdermal patches. It offers PrSandoz Dimethyl Fumarate Delayed-Release Capsules. The company’s products are used in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, oncology, ophthalmology, transplantation, and women’s health. Sandoz Canada Inc. was formerly known as Sabex, Inc. and changed its name to Sandoz Canada Inc. in September 2005. The company was founded in 1980 and is headquartered in Boucherville, Canada with an additional location in Princeton, new Jersey. Sandoz Canada Inc. operates as a subsidiary of Sandoz International GmbH.


Financial Information (Currency: CAD, in mm)
Total Revenue
 338.1
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
 900
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Robidoux, Michel
President and General Manager
Saucier, Michel 
Founder and Vice Chairman
Fournier, Martin 
Vice-President of Finance and IT
Riverin, Michel
Chief Scientific Officer
Danis, Christian
Vice President of Legal & Government Affairs, Corporate Secretary and General Counsel
Lambert, Annick
Executive Director of Communications
Beaudoin, Marc 
Vice-President of Strategy and Business Development
Gagnon, Jacquelin
Vice-President of Sales and Marketing
St-Pierre, Marc
Vice President of Human Resources
Francis, Richard D.
Division Head
Abran, Daniel 
Executive Director of Commercial Operations Quality
Bergeron, Jacques
Vice-President

Key Board Members
Name
Title
McGinley, Jack L.
Chairman of the Board
Saucier, Michel 
Founder and Vice Chairman


Primary Industry Classification
Pharmaceuticals


Primary Office Location
110 Rue de Lauzon | Boucherville, QC | J4B 1E6 | Canada
Fax: 800 343 8830

Parent Company
Sandoz International GmbH

Prior Investors
Capital d'Amérique CDPQ Inc., CDP Capital-Technology Ventures, PNC Erieview Capital, Roundtable Healthcare Management, Inc (Jack McGinley), RoundTable Healthcare Partners, L.P.


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Mar-01-2022
Mar-01-2022
Merger/Acquisition
Seller
Boucherville manufacturing plant
Delpharm SAS
Sandoz Canada Inc.
-
May-25-2018
Sep-06-2018
Merger/Acquisition
Seller
Major Sterile Manufacturing Facility and Development Center in Boucherville of Sandoz Canada Inc.
Avara Pharmaceutical Services, Inc.
Sandoz Canada Inc.
-
Jul-06-2004
Aug-13-2004
Merger/Acquisition
Target
Sabex, Inc. (nka:Sandoz Canada Inc.)
Sandoz International GmbH
Roundtable Healthcare Management, Inc Seller Funds:RoundTable Healthcare Partners, L.P.
565.00
Apr-21-2002
Apr-22-2002
Merger/Acquisition
Target
Sabex, Inc. (nka:Sandoz Canada Inc.)
Roundtable Healthcare Management, Inc

100.00
Nov-28-1996
-
Private Placement
Target
Sabex, Inc. (nka:Sandoz Canada Inc.)
Sofinov Societe Financiere d'Innovation (nka:CDP Capital-Technology Ventures),Capital d'Amérique CDPQ Inc.

17.52
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jan-06-2023
Product-Related Announcements
Sandoz Canada Launches PrSandoz® Sitagliptin and PrSandoz® Sitagliptin-Metformin
Nov-15-2022
Product-Related Announcements
Sandoz Canada Inc. Launches Sandoz Apremilast
Sep-21-2022
Product-Related Announcements
Sandoz Canada Continues to Expand Its Portfolio of Generic Products
Jul-05-2022
Product-Related Announcements
Sandoz Canada Inc. Expands Its Generics Portfolio with Three New Products
Mar-01-2022
M&A Transaction Closings
Delpharm SAS acquired Boucherville manufacturing plant from Sandoz Canada Inc.

Competitors
Apotex Inc., AstraZeneca Canada Inc., Bayer Inc., Bristol Myers Squibb Canada Co., Fresenius Kabi Canada Ltd., GlaxoSmithKline Inc., Janssen Inc., Johnson & Johnson Inc., Merck Canada Inc., Novartis Pharmaceuticals Canada Inc., Pfizer Canada Inc., Pfizer Inc. (NYSE:PFE), Pharmascience Inc., Teligent, Inc. (Out of Business), Teva Canada Limited, Valeant Canada Ltd., Viatris Inc. (NasdaqGS:VTRS)

M&A Advisors
Borden Ladner Gervais LLP, Ernst & Young Orenda Corporate Finance Inc., Kurmann Partners AG


Advisors
M&A Advisors
Borden Ladner Gervais LLP, Ernst & Young Orenda Corporate Finance Inc., Kurmann Partners AG


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 18, 2023 03:44 AM
Sandoz Canada Inc.
Sandoz Canada Inc
Reports
41
GlobalData

Jun 15, 2023 02:09 AM
Sandoz Canada Inc.
Sandoz Canada Inc
Reports
41
GlobalData

Mar 15, 2023 01:36 AM
Sandoz Canada Inc.
Sandoz Canada Inc
Reports
40
GlobalData

Dec 14, 2022 02:32 AM
Sandoz Canada Inc.
Sandoz Canada Inc
Reports
39
GlobalData

Sep 23, 2022 05:50 AM
Sandoz Canada Inc.
Sandoz Canada Inc
Reports
39
GlobalData

Jun 14, 2022 03:04 AM
Sandoz Canada Inc.
Sandoz Canada Inc
Reports
39
GlobalData

Mar 11, 2022 01:45 AM
Sandoz Canada Inc.
Sandoz Canada Inc
Reports
35
GlobalData

Dec 14, 2021 02:32 AM
Sandoz Canada Inc.
Sandoz Canada Inc
Reports
20
GlobalData

Sep 16, 2021 05:02 AM
Sandoz Canada Inc.
Sandoz Canada Inc
Reports
16
GlobalData

Jun 14, 2021 01:36 PM
Sandoz Canada Inc.
Sandoz Canada Inc
Reports
16


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Erelzi, Generic Sterile Injectables, Isoproterenol HCl Injection, Morphine Sulfate Injection, Omnitrope, PrSandoz Olmesartan, PrTOBRAMYCIN INHALATION SOLUTION, Sandoz Amphetamine XR, Sandoz Losartan, Sandoz Losartan HCT

Key Board Members Details
Name
Title
Phone
Fax
Email
McGinley, Jack L.
Chairman of the Board
(847) 739-3210
800 343 8830
jmcginley@roundtablehp.com
Saucier, Michel 
Founder and Vice Chairman
-
800 343 8830
-
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Robidoux, Michel
President and General Manager
-
800 343 8830
-
Saucier, Michel 
Founder and Vice Chairman
-
800 343 8830
-
Fournier, Martin 
Vice-President of Finance and IT
-
800 343 8830
-
Riverin, Michel
Chief Scientific Officer
-
800 343 8830
-
Danis, Christian
Vice President of Legal & Government Affairs, Corporate Secretary and General Counsel
-
800 343 8830
-
Lambert, Annick
Executive Director of Communications
-
800 343 8830
-
Beaudoin, Marc 
Vice-President of Strategy and Business Development
-
800 343 8830

Gagnon, Jacquelin
Vice-President of Sales and Marketing
-
800 343 8830
-
St-Pierre, Marc
Vice President of Human Resources
-
800 343 8830
-
Francis, Richard D.
Division Head
-
800 343 8830

Abran, Daniel 
Executive Director of Commercial Operations Quality
-
800 343 8830
-
Bergeron, Jacques
Vice-President
-
800 343 8830
-
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
